Farmak has expanded its portfolio with a new medicinal product — an injectable medicine used to control life-threatening bleeding.
The product is used as rescue therapy for bleeding from esophageal veins, the gastrointestinal tract, the genitourinary system, as well as for gastric and duodenal ulcers, uterine bleeding, and bleeding associated with surgical interventions. In gynecological practice, it may be applied locally during cervical surgeries. The medicine is also an important treatment option for severe complications of liver cirrhosis.
The introduction of this product into Farmak’s portfolio is an important step for Ukrainian healthcare. The medicine has become the first generic of its kind in Ukraine, increasing access to effective therapy for patients and expanding treatment options for physicians in critical situations.
Today, Farmak’s portfolio includes more than 450 medicinal products, and the company continues to systematically expand it, providing patients with modern, high-quality, and affordable medicines. Farmak supplies medicinal products to more than 60 countries worldwide, including 15 EU countries. All products are manufactured in compliance with the highest EU GMP (Good Manufacturing Practice) standards.
